P2, N=405, Completed, Eli Lilly and Company | Recruiting --> Completed

P2, N=59, Completed, Clexio Biosciences Ltd. | Recruiting --> Completed

P2, N=410, Recruiting, Eli Lilly and Company | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Jan 2025 --> Jul 2025

CLE (100 or 300 mg/kg/day) was orally administered daily from days 18 to 23, with dexamethasone (3 mg/kg/day) used as the positive control...The CLE100 and CLE400 groups exhibited a significant downregulation in eosinophil counts, cytokine levels, and immunoglobulin-E levels...Additionally, 50 µg/mL CLE and 2.5 µg/mL curcumin showed similar anti-inflammatory effects. Collectively, our findings revealed that CLE could suppress airway inflammation in asthmatic mice and A549 cells via oxidative stress-driven MAPK/MMPs signaling, suggesting that CLE could be developed as a potential treatment option for patients with asthma.

P2, N=54, Recruiting, Clexio Biosciences Ltd. | N=40 --> 54

P2, N=40, Recruiting, Clexio Biosciences Ltd.

P1, N=7, Completed, Eli Lilly and Company | Recruiting --> Completed

P2, N=410, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting

P1, N=7, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting

P2, N=410, Not yet recruiting, Eli Lilly and Company

Most insulinomas express SSTR2, which may be utilized in diagnostic imaging, and in planning individualized treatment strategies for insulinoma patients. Further studies are needed to clarify the association between SSTR profile and overall survival.